Result of AGM

Graft Polymer (UK) PLC

28 June 2024

 

28 July 2024

Graft Polymer (UK) Plc

(the "Company", "GPL", "Graft Polymer" or "Group")

Results of Annual General Meeting

Graft Polymer (UK) Plc (LSE: GPL), an innovative developer of biopolymer drug delivery systems aimed at enhancing the effectiveness of therapeutics for biopharmaceutical companies, is pleased to announce that all resolutions proposed at the Annual General Meeting of the Company held earlier today were duly passed.

The numbers of proxy votes received in advance of the meeting for each resolution are presented below:

Resolutions	Total For (i)		Total Against		Votes Total
	No. of votes	% of vote	No. of votes	% of vote
Resolution 1	40,983,414	100.00%	-	-	40,983,414
Resolution 2	40,983,414	100.00%	-	-	40,983,414
Resolution 3	40,983,414	100.00%	-	-	40,983,414
Resolution 4	40,983,414	100.00%	-	-	40,983,414
Resolution 5	40,983,414	100.00%	-	-	40,983,414
Resolution 6	40,983,414	100.00%	-	-	40,983,414
Resolution 7*	40,983,414	100.00%	-	-	40,983,414
Resolution 8*	40,947,383	99.91%	36,031	0.09%	40,983,414

Notes:

i  The "For" Proxy vote includes those giving the Chair of the AGM discretion

*Special resolutions

The full text of the resolutions can be found in the Notice of Annual General Meeting, which is available on the Company's website at: https://graftpolymer.com/shareholder-circulars/

Enquiries:

Graft Polymer (UK) Plc:

Anthony Tennyson, CEO and Executive Director: [e-mail]

Yifat Steuer, CFO and Executive Director: [e-mail]

Allenby Capital (Broker):

Phone: [phone]

Nick Naylor / Liz Kirchner (Corporate Finance)

Guy McDougall (Sales)

About Graft Polymer (UK) Plc

Graft Polymer (UK) Plc (LSE: GPL) is an innovative developer of biopolymer drug delivery systems dedicated to assisting biopharmaceutical companies in enhancing the effectiveness of their therapeutics. Our proprietary patented platform, a bioabsorbable self-nanoemulsifying drug delivery system (SNEDDS), represents a cutting-edge solution in drug delivery technology. By integrating active pharmaceutical ingredients (APIs) into our novel, patented delivery systems, we enable clients to improve the bioavailability, pharmacokinetics, and stability of their therapeutics.

 

END